Organon OGN Nexplanon/Implanon NXT — Number of pending claims
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Organon in its filing.
Tagged under the XBRL concept us-gaap:LossContingencyPendingClaimsNumber.
The source filing: Organon’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 8:46 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-029532
Merck is a defendant in lawsuits brought by individuals relating to the use of Nexplanon and Implanon™ (etonogestrel implant). There are two filed product liability actions involving Implanon, both of which are pending in the Northern District of Ohio as well as 56 unfiled cases involving Implanon alleging similar injuries, all of which have been tolled under a written tolling agreement. There is one matter involving Nexplanon pending in California state court. On March 12, 2026, the Company signed a Master Settlement Agreement with the attorneys representing plaintiffs and all but two of the claimants with unfiled cases, pursuant to which, in exchange for a confidential, but non-material settlement payment, all 56 plaintiffs and claimants will release the defendant parties from any liability for their filed and unfiled claims. As of March 31, 2026, Merck had 19 of such cases pending outside the United States, of which seven relate to Implanon and twelve relate to Nexplanon.
Item 1. Financial Statements (unaudited)
FAQ
- What is Organon's nexplanon/implanon NXT — number of pending claims?
- Organon (OGN) reported nexplanon/implanon NXT — number of pending claims of $19 in Q1 2026.
- How has Organon's nexplanon/implanon NXT — number of pending claims changed year-over-year?
- Organon's nexplanon/implanon NXT — number of pending claims decreased by 0.0% year-over-year, from $19 to $19.
- What is the long-term trend for Organon's nexplanon/implanon NXT — number of pending claims?
- Over 4 years (2021 to 2025), Organon's nexplanon/implanon NXT — number of pending claims has grown at a -6.0% compound annual growth rate (CAGR), from $91 to $71.
- What does nexplanon/implanon NXT — number of pending claims mean?
- This metric quantifies the volume of outstanding insurance or reimbursement claims associated with the specific product line that have been submitted but not yet finalized or paid. It provides insight into the efficiency of the revenue cycle management process and potential liquidity constraints related to accounts receivable. High levels of pending claims may indicate administrative bottlenecks or challenges in payer coverage and reimbursement policies.
Ask your AI about Organon's nexplanon/implanon nxt — number of pending claims.
Connect your AI assistant and compare segments, right in your chat.
